HYTERA-COMMUNICATIONS
15.5.2023 12:55:30 CEST | Business Wire | Press release
Hytera Communications (SZSE: 002583), a leading global provider of professional communications technologies and solutions, gathered its distribution, project, and application partners from over 50 countries and regions and successfully held Hytera Global Partner Summit (HGPS) 2023 on May 11th in Bali, Indonesia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230515005390/en/
Yelin Jiang, CEO of Hytera Group, delivering the keynote speech (Photo: Business Wire)
HGPS serves as a platform for Hytera partners to network with other like-minded professionals, gain insights into the latest trends of the industry, and learn what’s new with Hytera, including new products, solutions, and policies. The year 2023 marks the 30th anniversary of the company; therefore, HGPS 2023 was also a venue for the retrospect and celebration of the common journey shared by Hytera and its partners from across the world.
“The past 30 years have seen Hytera rose against numerous challenges and evolved from a product provider to a technology and solution provider. Now we are one of the leading companies in mission-critical and business-critical communications. Our talented engineers working in 8 R&D facilities across the world are the source of our confidence in future growth,” said Yelin Jiang, CEO of Hytera Group, in the keynote speech. “In 2022, Hytera released many innovative new products across multiple product series such as DMR radios, MCS & PoC radios, and body cameras. The new-generation H Series DMR radio was an instant success in the market.”
Thomas Lynch, executive research director of Omdia, was present to share the latest industry trends and developments with attendees, providing insights into the ever-changing industry landscape. According to Omdia’s analysis, in response to the market demands for data-rich features, Mission Critical Communications are moving towards a hybrid approach: keeping trusted LMR technology, such as TETRA, DMR, PDT for the indispensable voice communication in extreme situations and empowering the additional services and features with integrated LTE Broadband solutions. This is manifested in Hytera’s multi-front product development strategy.
Fully leveraging the venue of HGPS, Hytera brought regional partners into a global perspective with product solution deep dives and partners’ case studies. At the exhibition area, a complete portfolio of Hytera products and solutions were showcased, including TETRA Radios and Systems, DMR Radios and Systems, MCS & PoC Radios and Solutions, Body Camera Solutions, Multimedia Communication Platform, Control Room Solutions, 4G&5G Systems, and Fast Deployment Solutions. HGPS2023 invited some of Hytera ecosystem partners to showcase their value-added applications on top of Hytera products and they brought solutions such as encryptions, dispatching, satellite connectivity, and emergency coordination.
The Summit concluded on a high note with the Hytera 30th Anniversary and Awarding Ceremony, which acknowledged the performance and progress of partners in the year 2022. Golden Loyalty Awards was specially set up for HGPS2023 to celebrate the long-term partnership with and loyalty to the Hytera brand in the past three decades.
About Hytera
Hytera Communications Corporation Limited (SZSE: 002583) is a leading global provider of professional communications technologies and solutions. With voice, video and data capabilities, we provide faster, safer, and more versatile connectivity for business and mission critical users. We make the world more efficient and safer by enabling our customers to achieve more in both daily operations and emergency response. Learn more at https://www.hytera.com/en/home.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230515005390/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom